pembrolizumab
merck
['kn407', 'lcsm,(-blcsm)']
#esmo22: 5y os analysis of kn407 shows no benefit in #lcsm sq &lt;1% high medical need in this subgroup for new therapies.
I am physician and researcher passionate about advancing precision oncology and lung cancer treatments. Views are my own.